Securities Report - 22nd Period (2025/04/01 - 2026/03/31)
ADR120S Co., Ltd. has published the 22nd Period Securities Report. Detailed performance and financia… · 2026-06-26
株式会社ＡＤＲ１２０Ｓ News Releases
ADR Therapeutics Commences Joint Research with Medical Arc on Canine Joint and Inflammatory Diseases Using 'Neocella'
ADR Therapeutics, a subsidiary of ADR120S, has commenced research on the application of its next-gen… · 2026-05-22
ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University
ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Me… · 2026-05-15
ADR Therapeutics Launches Joint Research with Northern Farm on 'Neocella' to Improve Thoroughbred Breeding Disorders
ADR Therapeutics has announced a joint research agreement with Northern Farm to study the applicatio… · 2026-05-19
ADR120S Development Product "CrymEX" Confirmed to Meet Extracellular Vesicle Standards in Analysis Guided by Tokyo Medical University's Advanced Medical Research Institute
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03
ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University
ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Me… · 2026-05-15
ADR120S Development Product "CrymEX" Confirmed to Meet Extracellular Vesicle Standards in Analysis Guided by Tokyo Medical University's Advanced Medical Research Institute
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03
ADR120S Development Product "CrymEX" Confirmed to Meet Extracellular Vesicle Standards in Analysis Guided by Tokyo Medical University's Advanced Medical Research Institute
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03